Gilead Sciences (GILD) vs Neurocrine Biosciences (NBIX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Gilead Sciences (GILD) has outperformed Neurocrine Biosciences (NBIX) over the past year, gaining 24.4% versus a gain of 1.6%. Over five years, GILD leads with a +117.5% price change compared with +35.1% for NBIX. Gilead Sciences is the larger company by market cap ($182.40 billion vs $14.36 billion), about 12.7 times the size, while Neurocrine Biosciences is growing revenue faster (+21.4% vs +2.4%).
On valuation, Neurocrine Biosciences trades at a lower forward P/E (11.9x vs 14.9x for Gilead Sciences). Gilead Sciences pays a dividend yielding 2.19%, while Neurocrine Biosciences does not currently pay one. Gilead Sciences converts more of its revenue into profit, with a net margin of 28.9% versus 16.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GILD | NBIX |
|---|---|---|
| Share price | $147.10 | $141.25 |
| Market cap | $182.40B | $14.36B |
| 1-day change | +0.17% | -1.55% |
| YTD return | +19.85% | -0.41% |
| 1-year return | +24.40% | +1.56% |
| 5-year return | +117.51% | +35.12% |
| P/E ratio (TTM) | — | 20.71 |
| Forward P/E | 14.87 | 11.89 |
| EPS (TTM) | $-2.65 | $6.82 |
| Dividend yield | 2.19% | 0.00% |
| Annual dividend | $3.22 | $0.00 |
| Revenue (latest FY) | $29.44B | $2.86B |
| Revenue growth (YoY) | +2.40% | +21.45% |
| Net income (latest FY) | $8.51B | $478.60M |
| Gross margin | 78.83% | 98.18% |
| Operating margin | 34.04% | 21.64% |
| Net margin | 28.90% | 16.73% |
| 52-week high | $157.29 | $186.12 |
| 52-week low | $114.02 | $122.14 |
| Distance from 52-week high | -6.48% | -24.11% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +8.27% | +46.75% |
| Average volume | 5.99M | 1.30M |
| Shares outstanding | 1.24B | 101.65M |
| Employees | 17,000 | 2,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Gilead Sciences is about 12.7 times larger than Neurocrine Biosciences by market value ($182.40B vs $14.36B).
- GILD has outperformed NBIX by 22.8 percentage points over the past year.
- Gilead Sciences offers a meaningfully higher dividend yield (2.19% vs 0.00%).
- Gilead Sciences is more profitable, keeping 28.9 cents of every revenue dollar as net income versus 16.7 cents for Neurocrine Biosciences.
- Neurocrine Biosciences grew revenue faster in its latest fiscal year (+21.45% vs +2.40%).
About Gilead Sciences
GILD stock →Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17,000 employees
About Neurocrine Biosciences
NBIX stock →Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,500 employees
GILD vs NBIX FAQ
Which is bigger, Gilead Sciences or Neurocrine Biosciences?
Gilead Sciences (GILD) is larger, with a market capitalization of $182.40B compared with $14.36B for Neurocrine Biosciences (NBIX).
Which stock has performed better over the past year, GILD or NBIX?
GILD returned +24.40% over the past 12 months, compared with +1.56% for NBIX (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Gilead Sciences or Neurocrine Biosciences?
Gilead Sciences pays a dividend yielding 2.19%, while Neurocrine Biosciences does not currently pay a regular dividend.
Are Gilead Sciences and Neurocrine Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.